The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.
Request for Sample Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=49
Increasing Awareness Programs for Lung Cancer to Drive Growth of the Market
A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.
CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market. Revenue from CA tests will account for US$ 889.3 Mn by 2022-end. Angiogenesis inhibitor is expected to witness the fastest expansion among test type in the market, followed by HER 2 tests. Revenue from ALK tests for lung cancer diagnostics will continue to remain low in the market.
The report on the global market for lung cancer discusses such key factors that govern the economics of lung cancer diagnostics across the globe. Some of the key influences for the growth of global lung cancer diagnostics market include:
1- Rising presence of carcinogenic elements in common consumables
2- Surging exposure to toxic substances in factories & industrial settings
3- Lack of awareness related to causes, symptoms, and preventive measures for lung cancer
4- High healthcare costs, deterring lung cancer patients from seeking optimum diagnosis
Competition Tracking
Novel product launches for lung cancer diagnostics is a key strategy adopted by leading players in the global market, in order to increase their product portfolio. Fact.MR’s report profiles key market players, which include Illumina, Inc., Abbott Laboratories, Thermo Fischer Scientific, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, and Danaher Corporation.
Browse Full Report with TOC - https://www.factmr.com/report/49/lung-cancer-diagnostics-market
Table of Contents:
Chapter 1. Global Lung Cancer Diagnostics Market - Executive Summary. 12
Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14
2.1.2. Global Lung Cancer Diagnostics Market Definition. 14
2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Lung Cancer Diagnostics Market Dynamics. 15
2.3.1. Drivers. 15
2.3.2. Restraints. 15
2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Key Participants Market Presence (Intensity Map) By Region. 16
Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17
3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17
3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17
3.1.1.2. Market Share Comparison, By Region. 19
3.1.1.3. Y-o-Y growth Comparison, By Region. 19
3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20
3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20
3.1.2.2. Market Share Comparison, By Region. 22
3.1.2.3. Y-o-Y growth Comparison, By Region. 22
3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23
3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23
3.1.3.2. Market Share Comparison, By Region. 25
3.1.3.3. Y-o-Y growth Comparison, By Region. 25
3.1.4. Angiogenesis Inhibitor Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 26
3.1.4.2. Market Share Comparison, By Region. 28
3.1.4.3. Y-o-Y growth Comparison, By Region. 28
3.1.5. EGFR Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 29
3.1.5.2. Market Share Comparison, By Region. 31
3.1.5.3. Y-o-Y growth Comparison, By Region. 31
Continued…….
Check Discount on this Report - https://www.factmr.com/connectus/sample?flag=D&rep_id=49
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/